Anbio Biotechnology (NNNN) Receivables (2023 - 2025)

Anbio Biotechnology (NNNN) has 3 years of Receivables data on file, last reported at $3.7 million in Q4 2025.

• On a quarterly basis, Receivables rose 243.44% year-over-year to $3.7 million in Q4 2025; TTM through Dec 2025 was $3.7 million, a 243.44% increase from a year earlier, with the FY2025 full-year figure at $3.7 million, up 243.44% from the prior year.
• Receivables for Q4 2025 stood at $3.7 million, down from $3716.4 billion in the prior quarter.
• Over the last five years, Receivables for NNNN reached as high as $3716.4 billion in Q2 2025 and fell as low as $1.1 million in Q4 2024.
• Historically, Receivables has averaged $929.1 billion across 3 years, with a median of $2.8 million in 2023.
• Across the five-year window, Receivables sank 43.51% in 2024 and soared 243.44% in 2025, its largest moves.
• Year by year, Receivables stood at $1.9 million in 2023, then plunged by 43.51% to $1.1 million in 2024, then surged by 243.44% to $3.7 million in 2025.
• Per Business Quant data, the three most recent Receivables figures were $3.7 million in Q4 2025, $3716.4 billion in Q2 2025, and $1.1 million in Q4 2024.